Rheumatoid Arthritis. Rheumatoid arthritis, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Curcumin nanoformal drug with the specific name of Sina Curcumin produced by Elixir Nanocina Company, 40 mg capsule daily for a period of 3 months, in the group rec
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients are women The age range is between 18-65 years Measured by the European American College Rheumatology Criteria (EULAR-ACR) by a rheumatologist Their DAS (disease activity scort28) is between 8.2 and 5, which is assessed by a rheumatologist.
Exclusion criteria
Exclusion criteria: Refusal to give informed consent Chronic Diseases affecting ESR, CRP levels such as diabetes and heart disease Pregnancy and lactation Nervous disorders Abnormal Creatinine (greater than 1/5) Abnormal liver enzymes (AST-ALT) (3 times normal)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of TH17 cell number. Timepoint: Measurement of TH17 cell count at the beginning of the study (before the intervention) and 3 months after the start of the use of curcumin nano-formulation or placebo. Method of measurement: Flow cytometry method.;Abundance of Treg cell population (regulatory). Timepoint: Measurement of Treg cell count at the beginning of the study (before the intervention) and 3 months after the start of the use of curcumin nano-formulation or placebo. Method of measurement: Flow cytometry method.;Gene expression Lnc-HOTAIR (Long non coding). Timepoint: Evaluation of Lnc-HOTAIR gene expression at the beginning of the study (before intervention) and 3 months after starting the use of curcumin nano-formulation or placebo. Method of measurement: First the primer design, then the cDNA synthesis is measured with special kits and finally with real time PCR.;Gene expression Lnc-MEG3 (Long non coding). Timepoint: Evaluation of Lnc-MEG3 gene expression at the beginning of the study (before intervention) and 3 months after starting to use curcumin nano-formulation or placebo. Method of measurement: Measurement before intervention (curcumin or placebo) and 3 months after intervention.;Gene expression mir-20b (micro RNA). Timepoint: Evaluation of mir-20 gene expression at the beginning of the study (before the intervention) and 3 months after the start of curcumin nano-formulation or placebo. Method of measurement: First the primer design, then the cDNA synthesis is measured with special kits and finally with real time PCR.;Gene expression mir-223 (micro RNA). Timepoint: Evaluation of mir-223 gene expression at the beginning of the study (before intervention) and 3 months after starting to use curcumin nano-formulation or placebo. Method of measurement: First the primer design, then the cDNA synthesis is measured with special kits and finally with real time PCR.;Gene expression FOXP3. Timepoint: Evaluation of FOXP3 gene expression at the beginning of | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease activity in rheumatoid arthritis patients in the study groups. Timepoint: Before the start of the study and 3 months after taking the nanoformal drug curcumin. Method of measurement: Rheumatology criteria by European American College (EULAR-ACR), disease activity and number of sensitive and swollen joints and other related symptoms are evaluated by a rheumatologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarzieh Raisi
Yazd University of Medical Sciences
Outcome results
None listed